Monte Rosa Therapeutics, Inc. (GLUE) Stock Score, Valuation & Financial Research
Monte Rosa Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 37/100.
Quick answer for GLUE
Monte Rosa Therapeutics, Inc. currently has a Wall Street Score of 37/100. The stored market price is $14.07. Its financial score is 50/100. Its valuation score is 0/100. The latest WSS change is +2.6 points. These figures are a research snapshot, not a buy or sell recommendation.
What Monte Rosa Therapeutics, Inc. does
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Fo
GLUE financial snapshot
- Wall Street Score:
- 37/100
- Current price:
- $14.07
- Market capitalization:
- $1.19B
- Revenue:
- $28.7M
- Net income:
- $-161.1M
- Free cash flow:
- $-27.5M
- Cash:
- $90.1M
- Total debt:
- $38.0M
- EPS:
- -0.59
- Financial score:
- 50/100
- Valuation score:
- 0/100
- Revenue score:
- 0/100
What stands out
- Reported year-over-year revenue growth is -0.8%.
- Free cash flow is $-27.5M, showing cash burn in the current stored period.
- The balance sheet shows $90.1M of cash versus $38.0M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +2.6 points: GLUE increased 2.6 points because Moat improved by 25 points.
- The current research record carries a missing revenue history warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 50/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research GLUE
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.